Moreover, it has been shown that EGFR‐mutant NSCLC cells tolerated to short‐term EGFR‐TKI treatment possess elevated Mcl‐1 levels and can be sensitized to EGFR‐TKIs by targeting Mcl‐1 (Song et al., 2018). This evidence concerns the gene MCL1 and non-small cell lung carcinoma.